FORM 3

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

# INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Add Ludwig Kar		2. Date of Event Requiring Statement Month/Day/Year) 05/30/2007  3. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS INC [ FOLD ]									
(Last) (First) (Middle) C/O AMICUS THERAPEUTICS, INC.				Relationship of Reporting Person (Check all applicable)     Director		10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)			
6 CEDAR BROOK DRIVE						X Officer (give title below) Other (speci		, 10	Applicable Line)		
(Street) CRANBURY NJ 08512					Senior VP, Clinical	Kesearch			y One Reporting Person y More than One erson		
(City)	(State)	(Zip)									
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Securit			2. Amount of Securities Beneficially Owned (Instr. 4)				4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		d 3. Title and Amount of Securi Underlying Derivative Securit		ty (Instr. 4) Conve		se Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
		Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)			
Employee Stoc	k Option (righ	t to buy)	(1)	02/28/2016	6	Common Stock	60,000	5.33	D		
Employee Stoc	k Option (righ	t to buy)	(2)	02/28/2016	6	Common Stock	6,667	5.33	D		
Employee Stock Option (right to buy)		(3)	04/25/2017	7	Common Stock	40,000	13.43	D			

### **Explanation of Responses:**

- 1. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on February 21, 2007. The remaining options vest and become exercisable in a series of thirty-six successive equal monthly installments, beginning on March 1, 2007.
- 2. These options vest and become exercisable in a series of installments. The first installment, which consisted of 25% of the total aggregate number of options granted, vested on February 28, 2007. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 139 shares, beginning on March 1, 2007, with the final installment of 135 shares becoming exercisable on February 1, 2010.
- 3. These options vest and become exercisable in a series of installments. The first installment, which consists of 25% of the total aggregate number of options granted, will vest on April 25, 2008. The remaining options vest and become exercisable in a series of thirty-five successive equal monthly installments of 834 shares, beginning on May 1, 2008, with the final installment of 810 shares becoming exercisable on April 1, 2011.

/s/ Douglas A. Branch, Attorney-in-fact 05/30/2007

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

### AMICUS THERAPEUTICS, INC.

#### POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints John F. Crowley, John M. McAdam, Douglas A. Branch and James E. Dentzer, each individually, as the undersigned's true and lawful attorneys-in-fact to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Amicus Therapeutics, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
- (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of any such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that neither of the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, is assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 29th day of May, 2007.

/s/ Karin Ludwig

Name: Karin Ludwig